FDA Grants Fast Track Designation to Lantern Pharma's AI-Enhanced Drug LP-184 for Glioblastoma
Lantern Pharma Inc., an AI company pioneering cancer therapies, announces that the FDA has granted Fast Track Designation for its investigational drug, LP-184, to treat Glioblastoma. Currently in a Phase 1A clinical trial, LP-184 is being evaluated for safety and tolerability in various solid tumors, including GBM. Optimized through Lantern’s AI platform, RADR®, the drug aims to target mechanisms to combat challenging cancers. RADR® integrates over 100 billion data points, fueling Lantern’s drug portfolio and collaborations. Publish Date: 15-10-2024 Source: Lantern Pharma Inc. Glioblastoma (GBM) is the most aggressive among the diffuse gliomas originating from the astrocytic lineage. It ranks as the most prevalent malignant primary brain tumor, comprising 54% of all gliomas and 16% of primary brain tumors. GBM is classified as a malignant astrocytic tumors, earning a Grade IV designation according to the WHO classification. The exact cause of this disease remains unknown, exce